[gnso-gac-closed-generics] Facilitated Dialogue on Closed Generics: Welcome and Preliminary Administrative Information

Sophie Hey sophie.hey at comlaude.com
Fri Oct 14 10:17:46 UTC 2022


Hi Mary,

Thank you for sharing the below information.

At this stage I am free throughout January and am happy to work around others in the group who have pre-existing commitments.

Sophie

Sophie Hey
Policy Advisor
Com Laude
T +44 (0) 20 7421 8250
Ext 252

[cid:image001.png at 01D8DFBE.950D0B70]<https://comlaude.com/>
From: gnso-gac-closed-generics <gnso-gac-closed-generics-bounces at icann.org> On Behalf Of Mary Wong
Sent: 13 October 2022 22:25
To: gnso-gac-closed-generics at icann.org
Subject: [gnso-gac-closed-generics] Facilitated Dialogue on Closed Generics: Welcome and Preliminary Administrative Information

Hello everyone,

Thank you all again for agreeing to participate in the facilitated dialogue on the topic of Closed Generic gTLDs. The staff team supporting this work are happy to confirm that all participants appointed by the GAC, the GNSO and the ALAC (including the ALAC’s alternate member) have now been subscribed to this mailing list. This list is now active and available for your use.

Information about the Mailing List & Wiki Space:
Please note the email address for this list is gnso-gac-closed-generics at icann.org<mailto:gnso-gac-closed-generics at icann.org>. We will use this space to communicate information about scheduling, logistics and other administrative details, as well as to coordinate the asynchronous “pre-work” discussed during the Meet-and-Greet session at ICANN75. This work and the on-list interactions are integral to and an extension of the facilitated dialogue itself, so this list and postings to it will be closed to observers while the work is underway. For accountability and transparency purposes, however, the list will be archived once the dialogue has concluded.

In addition to this mailing list, staff has created a wiki space for the dialogue, which can be found at https://community.icann.org/x/6gTVD. As work progresses, we will post agreed publicly-accessible documents and relevant information to ensure that the work is documented appropriately, including agreed outcomes (if any) following the conclusion of the dialogue.

Location & Dates for an In-Person/Hybrid Dialogue:
As discussed during the Meet-and-Greet session at ICANN75, the relatively short timeline available to plan an in-person/hybrid meeting means that we will need to hold this meeting at an ICANN office. Taking into consideration the location of all participants and available office space, we propose to hold the meeting in Washington, DC, and as discussed at ICANN75, over two days in January 2023.

We recognize that you all have many commitments and very busy schedules and we wish therefore to ensure that planning can proceed as collaboratively and smoothly as possible, To enable us to start the internal processes necessary for the meeting and to allow you to plan your schedules as much in advance as possible, we ask that you each respond to this email with your January 2023 availability. With that information in hand, we hope that we can finalize the dates and other important details quickly.

Thank you for your attention and input. Please look out for additional follow-up emails from staff that will touch on the participation commitments we discussed briefly at ICANN75 as well as distribution of the Problem Statement and associated briefing paper.

Best regards,
Mary (on behalf of the staff team supporting the facilitated dialogue)
________________________________
The contents of this email and any attachments are confidential to the intended recipient. They may not be disclosed, used by or copied in any way by anyone other than the intended recipient. If you have received this message in error, please return it to the sender (deleting the body of the email and attachments in your reply) and immediately and permanently delete it. Please note that Com Laude Group Limited (the “Com Laude Group”) does not accept any responsibility for viruses and it is your responsibility to scan or otherwise check this email and any attachments. The Com Laude Group does not accept liability for statements which are clearly the sender's own and not made on behalf of the group or one of its member entities. The Com Laude Group is a limited company registered in England and Wales with company number 10689074 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England. The Com Laude Group includes Nom-IQ Limited t/a Com Laude, a company registered in England and Wales with company number 5047655 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Valideus Limited, a company registered in England and Wales with company number 6181291 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Demys Limited, a company registered in Scotland with company number SC197176 and registered office at 15 William Street, South West Lane, Edinburgh, EH3 7LL Scotland; Consonum, Inc. dba Com Laude USA and Valideus USA, a corporation incorporated in the State of Washington and principal office address at Suite 332, Securities Building, 1904 Third Ave, Seattle, WA 98101; Com Laude (Japan) Corporation, a company registered in Japan with company number 0100-01-190853 and registered office at 1-3-21 Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan; Com Laude Domain ESP S.L.U., a company registered in Spain and registered office address at Calle Barcas 2, 2, Valencia, 46002, Spain. For further information see www.comlaude.com<https://comlaude.com>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://mm.icann.org/pipermail/gnso-gac-closed-generics/attachments/20221014/e84a3e64/attachment-0001.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image001.png
Type: image/png
Size: 6936 bytes
Desc: image001.png
URL: <https://mm.icann.org/pipermail/gnso-gac-closed-generics/attachments/20221014/e84a3e64/image001-0001.png>


More information about the gnso-gac-closed-generics mailing list